Expression of biomarkers related with bone marrow cells in patients with acute myelogenous leukemia.
10.7534/j.issn.1009-2137.2014.05.001
- Author:
Xiao HUANG
1
;
Rong-Hua WANG
2
;
Dong-Yun LI
1
;
Zong-Lang LAI
1
;
Yu-Ting CHU
1
;
Yu ZHANG
1
;
Xin-Yi CHEN
2
;
Author Information
1. Department of Oncology and Hematology, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine, Beijing 100700, China.
2. Department of Oncology and Hematology, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine, Beijing 100700, China
- Publication Type:Journal Article
- MeSH:
Biomarkers;
analysis;
Bone Marrow Cells;
chemistry;
Humans;
Leukemia, Myeloid, Acute;
diagnosis;
NF-kappa B;
PTEN Phosphohydrolase;
Phosphatidylinositol 3-Kinases;
Prognosis;
TOR Serine-Threonine Kinases
- From:
Journal of Experimental Hematology
2014;22(5):1193-1198
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to investigate the expression of biomarkers (PTEN, mTOR, NF-kB, CD44, PI3K) related with bone marrow cells in patients with acute myelogenous leukemia. The immunohistochemical method was used to detect the expression of PTEN, mTOR, NF-kB, CD44, PI3K in 20 patients. The AML patients were divided into remission group and non-remission group after calculating the percentage of leukemia cells in bone marrow. The results showed that by optical microscopy, the positive expression rates of PTEN, mTOR, NF-kB, CD44 and PI3K in remission group were 33.3%, 33.3%, 77.8%, 22.2%, 0, respectively; meanwhile, in non-remission group, the positive expression rates of above-menthioned biomarkers were 63.6%, 18.2, 90.9, 63.6%, 0, respectively. The percentage and mean OD for PTEN and CD44 were statistically different between the two groups (P < 0.05), but for mTOR, NF-kB and PI3K were not statistically differenly (P > 0.05). It is concluded that the high expression of PTEN and CD44 can be regarded as an important index for diagnosis and prognosis in acute myelogenous leukemia.
